While some conclusions can be extrapolated from other cancers—like the need to ensure sufficient sample size (> 2 cm) or the effects of PD-L1 glycosylation before staining and analysis—their adaptation to TNBC protocols requires further research [25, 26]. This evidence concerns the gene CD274 and cancer.